We enrolled 85 patients with invasive cervical cancer and collected cervicovaginal lavage samples at each clinical visit for diagnosis, staging, treatment, and follow-up. Lavage samples were tested by L1 consensus polymerase chain reaction for human papillomavirus (HPV). Results were compared with HPV demonstrated in tumor tissue and the clinical status at time of sample collection. Sensitivity and specificity of the lavage for detection of tumor HPV, determined on the basis of results of tests on lavage samples collected prior to therapy, were found to be 56% and 76.9%, respectively. The proportion of lavage samples detecting tumor HPV decreased significantly with treatment, from 0.54 at diagnosis to 0.03 at complete response (P õ .001). Local treatment failure was associated with increased detection of tumor HPV; however, no samples were positive prior to clinically detected treatment failure. These results suggest that cervicovaginal lavage is not an effective sampling method for epidemiological analysis of HPV in cervical tumors.
Cervical cancer remains a significant public health concern specimens could then be a useful marker for monitoring patients during therapy to detect minimal residual disease and in the United States. While the incidence of invasive cervical cancer has decreased, largely because of secondary prevention early recurrence. by cytological screening, stage-specific cervical cancer death rates have not substantially changed over the last 2 decades.
Materials and Methods
Most patients who receive curative therapy achieve at least an initial complete clinical response; however, there is no effective Patient Population treatment for cancer unresponsive to initial therapy or for recurAll patients with cervical cancer of FIGO (International Fedrent cervical cancer. In most instances these patients will die eration of Gynecology and Obstetrics) stage Ia or greater that of their cervical tumors. If treatment failures could be detected had been diagnosed since June 1986 and who attended the earlier than current clinical methods permit, perhaps salvage Grady Memorial Hospital and Clinics (GMHC) between April therapy would be more successful.
1992 and February 1995 were asked to participate in this study. This study was designed to determine whether detection of Once a patient was enrolled, clinical data and specimens were human papillomavirus (HPV) in cervicovaginal lavage samples collected at each subsequent routine visit for treatment or folwas associated with the clinical status of cervical disease for low-up. The patient's disease status at each visit was deterpatients with invasive cervical cancer at diagnosis, as well as mined by physical examination, supplemented by radiological during therapy and follow-up. The hypothesis was that tumor and histologic studies as appropriate, and was classified as cells collected in lavage samples would contain HPV DNA follows: (1) diagnosis (DX), tumor prior to treatment; (2) partial detectable with a sensitive PCR assay. HPV DNA in lavage response (PR), decrease in size of tumor during radiotherapy; (3) complete response (CR), no evidence of tumor during or following treatment; or (4) treatment failure (TF), tumor (confirmed by biopsy) following curative radiotherapy or recurrence lin and eosin staining of initial, middle, and final sections to were analyzed by type-specific hybridization to probes for HPV 16, 18, 31, 33, 35, and 56. Products not hybridizing were verify that recut sections were representative of tumor histology. A new disposable microtome blade was used for each sequenced as described previously [2] . block to minimize the potential for HPV DNA cross-contamination.
Data Analysis
The type of HPV detected in the primary tumor by in situ Lavage Specimens hybridization or PCR was defined as the tumor type HPV. HPV We used cervicovaginal lavage during pelvic examination detected in each lavage sample was compared with HPV in as a noninvasive means of sampling the lower genital tract at tumor. The association between tumor type HPV in the lavage each visit [1] . This provided exfoliated cells of all areas of the specimen and disease status was tested by means of Fisher's lower genital tract (normal as well as tumor). After visualizaexact test. Lavage samples collected at diagnosis were used tion of the cervix or vaginal apex with a disposable plastic to calculate the sensitivity and specificity of this method for speculum, the cervix and vagina were irrigated with 10 mL of detection of tumor type HPV. If multiple samples from an normal saline. The irrigating fluid was collected with gentle individual patient had been obtained prior to therapy, only the aspiration, and the resulting lavage sample was stored within first sample was used for the sensitivity/specificity calculations. 2 hours of collection at 070ЊC. Prior to HPV testing, the samThe ability to detect tumor type HPV in lavage as a function ples were thawed and cells were concentrated by low-speed of disease status was evaluated for all patients with HPVcentrifugation. Cells were resuspended at 1:10 dilution (volpositive primary tumors by two approaches. In the first, all ume:volume) in PBS. In the rare instances that the estimated samples were grouped according to disease status at lavage pellet volume was õ50 mL, we added 450 mL of saline. A specimen collection, and the proportion positive for tumor HPV 50-mL aliquot of the resulting suspension was processed for was calculated. This simple proportion could be inaccurate PCR. The remainder of the sample was refrozen for long-term because some individuals had more than one clinical visit and storage. PCR testing was performed as samples accumulated, therefore more than one lavage during a particular disease stain batches of 12. tus (e.g., 6 visits during following up, all in complete response).
In the second approach, to account for multiple visits, we initially calculated the proportion of tumor-positive lavage speci- were compared with use of the Fisher's exact test. BCIP/NBT color development, and nuclear fast red counterOne problem with pooling lavage samples from all patients stain. Optimal pretreatment conditions were determined for is that those enrolled at diagnosis might not be comparable to each block, with use of results of human placental DNA hybridthose enrolled months to years after therapy, even when ization (an endogenous positive control) as a guide. Sensitivity grouped by disease status at time of sample collection. To of each assay was monitored with detection of HPV 16 in minimize this problem, patients were stratified by cohorts based sections of formalin-fixed, paraffin-embedded cell blocks of on their disease status at the time of enrollment. The association SiHa cells (1 -2 copies of HPV/cell).
of tumor type HPV detection in lavage samples and disease L1 consensus primer PCR. L1 consensus PCR was used status was determined for each cohort as described above. as previously described [2] to detect HPV DNA in formalinfixed, paraffin-embedded tissue samples and, with minor modiResults fications, for lavage samples. Proteinase K predigestion was used for both types of samples. In brief, sample DNA integrity Study Population and the absence of PCR inhibitors were monitored by amplification of b-globin DNA in replicate tubes. For lavage samples Characteristics of the 85 study patients are shown in table 1, grouped by disease status at enrollment (cohorts) and summathe usual input volume per PCR tube was 5 mL of the 1:10 cell suspension, but occasionally (Ç10% of samples) the volume of rized for the total population. The DX and CR cohorts accounted for the majority of the patients (45% and 46%, respectemplate had to be increased or decreased to amplify b-globin. If this adjustment was not successful, DNA was extracted from tively). The patient age at diagnosis of invasive cervical cancer ranged from 28 to 85 years (mean, 51; median, 50). Most an additional 50 mL of lavage with phenol:chloroform extraction and ethanol precipitation. Successful amplification of patients (82%) were black and most (86%) had early-stage (I or II) disease. b-globin was achieved for all lavages samples. PCR products / 9c46$$fe18 01-08-98 22:55:50 cida UC: CID 
Sensitivity and Specificity of Lavage
Of the 85 patients, 76 (89%) received curative therapy: surgery (35%), radiation (45%), or combined surgery and radiation Cervicovaginal lavage samples collected at the time of diag-(9%). Three patients (4%) received palliative therapy and six nosis should contain tumor cells. Results for these samples will (7%) were untreated. Time of follow-up was calculated from reflect the sensitivity and specificity of this method of sample date of staging and ranged from 0.2 to 108.6 months. As excollection and analysis for detection of tumor-associated HPV. pected, median follow-up time was shortest for the DX cohort
We collected 49 cervicovaginal lavage specimens from 38 paand longest for the CR cohort. We collected 1 -12 lavage samtients with newly diagnosed cervical cancer. In the cases in ples from each patient, for a total of 348 specimens. Of these, which samples were obtained more than once prior to therapy, 268 samples were collected from the 63 patients with HPVonly the first sample was included in the sensitivity/specificity positive tumors. 
/ 9c46$$fe18
01-08-98 22:55:50 cida UC: CID (table 4) . In this lected from patients with local recurrence, and no samples from cross-sectional look at the population, tumor HPV was not patients with only distant failure contained tumor HPV (10/18 vs. 0/7; P Å .02, Fisher's exact test). Review of lavage results for those patients with eventual treatment failure did not dem- most cervical cancers [6, 7] . However, several factors limit the CR (n Å 59) .03 .15
usefulness of HPV as a molecular marker for cervical cancer. phologically normal epithelium adjacent to cervical cancer or ‡ Compared with lavage specimens collected at CR: P õ .001, Fisher's exact test.
genital warts [9, 10] . These observations raise the possibility / 9c46$$fe18 01-08-98 22:55:50 cida UC: CID that the genital tract of cervical cancer patients is involved in A smaller, more recent study compared hybrid capture detection of HPV in paired lavage and cervical biopsy specimens a ''field effect'' of latent or occult HPV infection that may not be eliminated by eradication of the neoplastic tissue. In addi- [14] . For 34 paired samples, the sensitivity and specificity of lavage for detection of biopsy HPV were 77% and 38%, respection, the patient's cervical tumor may be associated with one HPV type and the patient coinfected with another type.
tively. The low sensitivity resulted from the relatively large numbers of paired lavage-positive/biopsy-negative samples, In our patients, HPV DNA was detected in 74% of primary tumors by in situ hybridization or L1 consensus PCR. The proporand the authors attribute this to low-copy HPV infection missed in the biopsy. While the histology of the biopsy specimen tested tion of HPV-negative tumors is higher than that reported in several other studies [6, 11] . This may reflect differences in the for HPV was not determined, the findings from additional biopsy specimens obtained at the same colposcopy ranged from patient populations or methodologies for HPV detection. In our study, each assay for detection of HPV in tumor involved histonormal to high-grade dysplasia. These findings are closer to our results, although our sensitivity was lower because of lavagelogically confirmed tumor tissue. In most cases HPV was localized to the tumor by in situ hybridization, and all PCR products negative/tumor-positive samples.
While we did not test for HPV copy number, invasive canwere verified by type-specific hybridization or sequencing.
In addition to use of a good molecular marker for disease, cers frequently have lower copy numbers than dysplasias, which may be one reason for the lower sensitivity in our study. development of a molecular assay to monitor disease requires samples that are representative of the patient's disease state.
We conclude that cervicovaginal lavage samples are not ideal for molecular epidemiological studies of cervical cancer and Cervicovaginal lavage is a noninvasive method for collection of cells representative of the cervical/vaginal area and is the that the validity of the correlation between HPV detection in lavage specimens and HPV within cervical lesions needs to be currently accepted method for sampling cervical disease [1]. This study utilized PCR detection of HPV DNA in cervicovagireexamined. Treatment of cervical cancer did result in elimination of nal lavage specimens as a molecular assay for monitoring cervical cancer in patients with HPV-positive primary tumors.
tumor HPV from the genital tract. For the longitudinal analysis of the DX cohort, proportions of samples with tumor HPV We assumed cervicovaginal lavage samples collected from cervical cancer patients prior to therapy would contain tumor decreased from 54% at DX to 3% during CR (table 3) . The type of therapy or stage of disease did not influence these cells. However, only about half of these lavage samples from patients with HPV-positive tumors had detectable HPV. Comfindings. Similar results were found in the cross-sectional analysis including enrollment lavage for all patients with HPVpared with HPV detection within histologically confirmed tumor, the sensitivity and specificity of cervicovaginal lavage positive tumors (table 4) . The strength of the observation that elimination of tumor is associated with elimination of tumor for detection of tumor HPV type were only 56% and 76.9%, respectively. This low sensitivity contrasts markedly with the HPV is weakened by the limits in sensitivity of lavage sampling. As expected, detection of nontumor HPV did not signifioriginal descriptions of cervicovaginal lavage [1, 12, 13] . These studies, in women referred for colposcopy, all found lavage to cantly vary with disease state. HPV detection in lavage specimens from patients with HPV-negative primary tumors also be superior to other methods such as scrape or cytobrush cervical sampling. Because the authors assumed that detection of showed no variation with disease status. We conclude that cervicovaginal lavage is not the optimal more HPV reflected better sampling, their results could simply indicate a higher yield of cells or the contribution of HPV from sampling method for molecular epidemiological analysis for HPV in cervical tumors. Within the limits of the sampling and sites other than the cervix. Even with cervicovaginal lavage, the authors reported that 10% of their samples yielded inadeassay methods used in this study, tumor HPV was significantly less likely to be found in the genital tract when the patients quate DNA for Southern blot analysis [13] .
In the first two studies described [1, 12] , no attempt was made achieved complete clinical response to curative therapy, regardless of the type of therapy. Lavage samples did detect local to establish an association between results and cytology or biopsy findings. In the third study [13] the authors compared lavage recurrence of tumor, but only at the time when recurrences were detected clinically. Improved sampling methods need to with cervical biopsy (n Å 112) and found that lavage had 98% sensitivity and 61% specificity for detection of biopsy HPV.
be evaluated before molecular detection of tumor HPV could be incorporated into clinical management of cervical cancer. Because more HPV was detected in the lavage samples, the authors again concluded that it was a more sensitive method.
